跳到正文
原文
Medical Xpress·· 2026-10-14精选AI 评分64

Aarhus University 利用 prime editing 在患者自体造血干细胞中修复 GATA2 缺陷

Prime editing repairs immune disorder defect in patient's own blood stem cells

AI 导读

Aarhus University 的研究人员利用 prime editing 技术成功在患者自体的造血干细胞中部分修复了 GATA2 缺陷。这项发表于 Science Translational Medicine 的研究显示,基因编辑后正常功能的基因拷贝比例从 50% 提升至 70%,并观察到受影响蛋白质功能的改善。

推荐理由

研究利用基因编辑技术修正了特定患者的缺陷,正常基因比例由 50% 提升至 70%。

正文 · 原文
New gene-editing technology brings genetic diseases closer to treatment
Intranuclear staining for GATA2 in K562 cells. Credit: Science Translational Medicine (2026). DOI: 10.1126/scitranslmed.aec7031

Some people are born with a defect in their genetic material that prevents their immune system from functioning properly. In people with a condition known as GATA2 deficiency, the body does not produce enough immune cells, leaving them at increased risk of infections and disease. Now, researchers at Aarhus University have demonstrated that they can repair the genetic defect directly in patients' own blood stem cells.

Using a new technique called prime editing, the researchers have successfully corrected part of the genetic defect in stem cells taken from a patient. According to Jonas Holst Wolff, a postdoctoral researcher at the Department of Biomedicine who conducted the study together with professor Jacob Giehm Mikkelsen, the technique could have significant implications for patients with genetic disorders in the future.

"We have shown that it's possible to repair the genetic defect directly in a patient's own stem cells. This brings us one step closer to a treatment that addresses the underlying cause of the disease rather than simply treating its consequences."

Prime editing builds on the well-established CRISPR technology but works in a different way.

Traditional CRISPR involves cutting through DNA to make changes. This can affect the cells and, in some cases, lead to unintended changes elsewhere in the genetic material.

With prime editing, the DNA is not cut all the way through. Instead, researchers can insert a small piece of correct DNA at the precise location of the defect. This makes the method more precise and gentler on the stem cells, while also reducing the risk of side effects.

The work is published in the journal Science Translational Medicine.

From 50% to 70% normally functioning genes

Patients with GATA2 deficiency have one normal copy and one disease-causing copy of the affected gene. This means that around half of the gene copies in their stem cells function normally to begin with.

Following gene editing, the proportion of normally functioning gene copies increased from 50% to 70%. The researchers also observed an improvement in the function of the protein affected by the disease.

"This shows that we do not necessarily need to correct every gene copy. What matters is whether we can improve the cells' function enough to make a difference for the patient," explains Wolff.

Although the study suggests that prime editing is effective, the method is not yet ready for use in patients. The next major step is for the researchers to demonstrate that the technique can be used to treat the much larger number of stem cells needed for a patient to receive their own gene-edited stem cells.

The researchers also need to establish which patients with immune deficiencies would benefit most from the treatment. Some patients with GATA2 deficiency can currently be treated with stem cells from a donor, but prime editing could be particularly important for patients who have no other treatment options.

According to Wolff, prime editing could also have significant implications for patients with genetic defects other than GATA2 deficiency.

"In principle, the same approach could be used to treat other inherited diseases, provided we know the precise genetic defect responsible," he says. "Our goal is to develop a treatment tailored to the specific genetic defect in each individual patient. If we succeed, it could open up new possibilities for people with rare inherited diseases."

Publication details

Jonas H. Wolff et al., Prime editing of human hematopoietic stem cells for correction of GATA2 deficiency, Science Translational Medicine (2026). DOI: 10.1126/scitranslmed.aec7031

Journal information: Science Translational Medicine

Who's behind this story?

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Prime editing repairs immune disorder defect in patient's own blood stem cells (2026, October 13) retrieved 13 October 2026 from https://medicalxpress.com/news/2026-10-prime-immune-disorder-defect-patient.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com